1 Soaring Growth Stock That Could Rise Another 53%, According to Wall Street
Investors looking for stocks that can produce swift and dramatic gains recently found what they wanted with Iovance Biotherapeutics (NASDAQ: IOVA). Over the past three months, shares of the cancer drug developer nearly tripled in value.
Despite an already big run-up, investment bank analysts who follow Iovance closely think there's more upside. A consensus price target of $24.42 on the stock implies a gain of 53% from recent prices.
Whenever you see eye-popping predictions from Wall Street analysts, it's important to remember that those predictions come with caveats. In the case of Iovance, further gains rely on the successful launch of its new cancer therapy and more.
Source Fool.com
